Nivolumab is a monoclonal antibody that works by binding to a protein called PD-1 on a type of immune cell called T-cell.

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

Orencia sales $770M, down 2% y/y; Q1 Yervoy sales $624M, up 9% y/y.Stay Ahead of the Market: Discover outperforming stocks ...

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.